№ lp_1_2_19253
File format: docx Character count: 35212 File size: 135 KB
This PGD outlines the administration of a pneumococcal vaccine (PCV20) for specific groups, in line with the UK national immunization program and guidelines for pneumococcal disease management.
Year: 2025
Region / city: England
Topic: Immunization
Document type: Patient Group Direction (PGD)
Authoring body: UK Health Security Agency (UKHSA)
Target audience: Healthcare professionals involved in immunization programs
Period of validity: 17 December 2025 - 17 December 2028
Approval date: 9 December 2025
Review date: 17 July 2028
Expiry date: 17 December 2028
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
PNEUMOCOCCAL CONJUGATE VACCINE, 20-VALENT, 0.5 mL pre-filled syringe, Prevenar 20®, PFIZER AUSTRALIA PTY LTD
Year: 2023
Region / city: Australia
Subject: Pneumococcal vaccine
Document type: Submission
Organ / institution: Therapeutic Goods Administration (TGA), Pharmaceutical Benefits Advisory Committee (PBAC)
Author: Pfizer Australia Pty Ltd
Target audience: Healthcare professionals, public health policymakers
Period of validity: Ongoing
Approval date: 27 April 2023 (FDA approval)
Amendment date: 20 December 2022 (TGA submission)
Background: This document presents the submission for the 20-valent pneumococcal conjugate vaccine to be listed on the National Immunisation Program in Australia for specific paediatric populations.
Pneumococcal polysaccharide conjugate vaccine (adsorbed) Patient Group Direction (PGD)
Year: 2025
Region / city: England
Topic: Immunization
Document type: Patient Group Direction (PGD)
Organization / institution: UK Health Security Agency (UKHSA)
Author: Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience: Healthcare professionals involved in immunization
Period of validity: From 5 January 2026 to 5 January 2029
Approval date: 5 January 2026
Amendment date: 2 June 2025, 16 December 2025
Description: A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Pneumococcal polysaccharide vaccine (PPV23) Patient Group Direction, version 5.00
Publications gateway number: GOV-16528
Reference number: PPV23 PGD
Version: 5.00
Valid from: 1 September 2024
Review date: 1 September 2026
Expiry date: 1 March 2027
Vaccine: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Programme: National immunisation programme against pneumococcal disease
Target population: Individuals aged 65 years and over and individuals aged 2 years and over in clinical risk groups
Geographical scope: England
Legal framework: Human Medicines Regulations 2012, Schedule 16 Part 2
Issuing organisation: UK Health Security Agency
Developing body: Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
Authors: Christina Wilson; Professor Shamez Ladhani; David Green
Approval status: Ratified by the UKHSA Medicines Governance Committee
Document type: Patient Group Direction
PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE, 15 VALENT ADSORBED, 0.5 mL pre-filled syringe, Vaxneuvance® Merck Sharp & Dohme (Australia) Pty Ltd.
Year: 2021
Region / City: Australia
Topic: Pneumococcal vaccine submission
Document type: Submission for listing on the National Immunisation Program
Author: Merck Sharp & Dohme (Australia) Pty Ltd
Target audience: Health professionals, regulatory bodies, policy makers
Period of validity: Ongoing
Approval date: 16 July 2021 (FDA approval), 14 October 2021 (EMA recommendation)
Date of changes: Not specified
Context: A clinical submission for the inclusion of a 15-valent pneumococcal conjugate vaccine (PCV15) on the National Immunisation Program for adults at risk of pneumococcal disease.
MENINGOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE SEROGROUPS A, C, W-135 and Y
Year: 2017
Region / city: Australia
Theme: Meningococcal Vaccination
Document Type: Application for Vaccine Listing
Organization / institution: National Immunization Program (NIP)
Author: Pfizer Australia Pty Ltd
Target Audience: Health professionals, adolescents, school-based vaccination program administrators
Validity Period: Not specified
Approval Date: 29 August 2013
Amendment Date: Not specified
Note: Contextual description
PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE, 13-VALENT ADSORBED
Year: 2016
Region / City: Australia
Theme: Pneumococcal disease prevention
Document Type: Submission
Organization / Institution: Pfizer Australia Pty Ltd
Author: Pfizer Australia Pty Ltd
Target Audience: Healthcare professionals, policymakers, public health authorities
Period of Validity: Not specified
Approval Date: Not specified
Date of Changes: Not specified
Topics: PCV20 20-valent polysaccharide